Intelligent Investor

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.110 0.005 (4.35%)

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg
Gain/Loss
$45 Investor Webinar Notification - SPL Business Update 20 May 2024 10:27AM $0.115 $0.110 $0.120 fallen by 4.35%
$45 Change in substantial holding 16 May 2024 4:48PM $0.115 $0.110 $0.120 fallen by 4.35%
$45 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2024 9:42AM $0.135 $0.110 $0.120 fallen by 18.52%
$45 Change in Director's Interest Notice - R Thomas 17 Apr 2024 3:03PM $0.130 $0.110 $0.120 fallen by 15.38%
$45 Change in Director's Interest Notice - R Basser 16 Apr 2024 2:09PM $0.125 $0.110 $0.120 fallen by 12%
$45 Change in Director's Interest Notice - R Thomas 15 Apr 2024 2:17PM $0.130 $0.110 $0.120 fallen by 15.38%
$45 Investor Webinar Notification SPL Medicxi Partnership 8 Apr 2024 10:02AM $0.125 $0.110 $0.120 fallen by 12%
$45 Starpharma and Medicxi Partnership Petalion Therapeutics 8 Apr 2024 9:25AM $0.125 $0.110 $0.120 fallen by 12%
$45 S&P DJI Announces March 2024 Quarterly Rebalance 1 Mar 2024 5:03PM $0.130 $0.110 $0.120 fallen by 15.38%
$45 Half Yearly Report and Accounts 28 Feb 2024 9:38AM $0.130 $0.110 $0.120 fallen by 15.38%
$45 VivaGel BV US FDA Appeal Outcome 19 Feb 2024 9:37AM $0.145 $0.110 $0.120 fallen by 24.14%
$45 Application for quotation of securities - SPL 6 Feb 2024 2:05PM $0.145 $0.110 $0.120 fallen by 24.14%
$45 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2024 9:34AM $0.150 $0.110 $0.120 fallen by 26.67%
$45 Viraleze shows antiviral efficacy in COVID-19 patients 29 Jan 2024 9:16AM $0.145 $0.110 $0.120 fallen by 24.14%
$45 VivaGel BV sales and distribution agreement MENA region 22 Jan 2024 1:15PM $0.155 $0.110 $0.120 fallen by 29.03%
$45 DEP cabazitaxel data presentation at ASCO GI cancer meeting 19 Jan 2024 10:18AM $0.150 $0.110 $0.120 fallen by 26.67%
$45 Notification of cessation of securities - SPL 12 Jan 2024 2:13PM $0.165 $0.110 $0.120 fallen by 33.33%
$45 Final Director's Interest Notice - J Fairley 12 Jan 2024 2:12PM $0.165 $0.110 $0.120 fallen by 33.33%
$45 Appendix 3X - Cheryl Maley 12 Jan 2024 2:06PM $0.165 $0.110 $0.120 fallen by 33.33%
$45 Notification regarding unquoted securities - SPL 12 Jan 2024 2:05PM $0.165 $0.110 $0.120 fallen by 33.33%
$45 Application for quotation of securities - SPL 21 Dec 2023 2:20PM $0.170 $0.110 $0.120 fallen by 35.29%
$45 Positive DEP docetaxel Phase 2 results 19 Dec 2023 8:31AM $0.160 $0.110 $0.120 fallen by 31.25%
$45 Change in Director's Interest Notice - J Fairley 8 Dec 2023 2:06PM $0.135 $0.110 $0.120 fallen by 18.52%
$45 Notification regarding unquoted securities - SPL 8 Dec 2023 2:01PM $0.135 $0.110 $0.120 fallen by 18.52%
$45 Starpharma to present DEP at Radiopharmaceuticals Summit 6 Dec 2023 10:37AM $0.133 $0.110 $0.120 fallen by 16.98%

1 - 25 of 758 results

Page 1 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.